2021
DOI: 10.1089/jop.2021.0040
|View full text |Cite
|
Sign up to set email alerts
|

Corticosteroids in the Management of Infectious Keratitis: A Concise Review

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

0
3
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(3 citation statements)
references
References 88 publications
0
3
0
Order By: Relevance
“…Most of the treatments for BK aim to inhibit bacterial growth and control corneal inflammation with adjuvant steroid drugs, such as medroxyprogesterone . The use of steroid drugs, however, may reduce the secretion of fibrin and growth factors, resulting in opaque corneal tissue or ecchymosis that affects vision . Thus, the above treatments do not satisfactorily promote corneal wound healing.…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Most of the treatments for BK aim to inhibit bacterial growth and control corneal inflammation with adjuvant steroid drugs, such as medroxyprogesterone . The use of steroid drugs, however, may reduce the secretion of fibrin and growth factors, resulting in opaque corneal tissue or ecchymosis that affects vision . Thus, the above treatments do not satisfactorily promote corneal wound healing.…”
Section: Introductionmentioning
confidence: 99%
“…8 The use of steroid drugs, however, may reduce the secretion of fibrin and growth factors, resulting in opaque corneal tissue or ecchymosis that affects vision. 9 Thus, the above treatments do not satisfactorily promote corneal wound healing. Currently administered drugs are mostly small molecules, but there is much room for improvement in terms of bioavailability and corneal retention.…”
Section: ■ Introductionmentioning
confidence: 99%
“…It has been hypothesized that local metabolism of cortisol could take place at the ocular surface as cortisol could be produced by corneal epithelial cells [13]. In clinical practice, to control inappropriate corneal inflammation and relieve patients' symptoms, topical GCs are part of most therapeutic regimens, even in infectious keratitis [14], although they might delay corneal epithelial wound healing [15]. However, the effects of GCs vary as a function of the dose, the duration and timing of use, and is dependent on their chemical formulation.…”
Section: Introductionmentioning
confidence: 99%